Author

F. Colavita

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Immunology· 2 Biochemistry· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 3 Research Focus:host-pathogen & immune response· 3 Organism:mouse· 3 Research Focus:drug response / drug discovery· 2 Assay:proteomics· 2 Research Focus:benchmarking· 1 Organism:human· 1 Assay:imaging· 1

Frequent Co-Authors

G. Matusali· 3 shared D. Lapa· 2 shared A. Challis· 1 shared A. Conforti· 1 shared A. Folgori· 1 shared A. Lahm· 1 shared A. Leuzzi· 1 shared A. M. Contino· 1 shared

Activity by Year

2020-2021 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 27 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

3 shared papersImmunology

G. Matusali

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

ImmunologybioRxivPreprintJun 14, 2021

COVID-eVax, an electroporated plasmid DNA vaccine candidate encoding the SARS-CoV-2 Receptor Binding Domain, elicits protective immune responses in animal models of COVID-19

A. Conforti, E. Marra, F. Palombo…·De F

This paper evaluates a DNA vaccine candidate, COVID-eVax, which induces strong neutralizing antibodies and T cell responses against SARS-CoV-2 in animal models, showing protective effects against viral challenge.

DOI 10.1101/2021.06.14.448343

mouserat

𝕏 PostBluesky

ImmunologybioRxivOct 22, 2020

Immunogenicity of a new gorilla adenovirus vaccine candidate for COVID-19

A. Vitelli, S. Capone, A. Raggioli…·S. Colloca

This paper evaluates a gorilla adenovirus vaccine candidate for COVID-19, showing it is immunogenic in mice and macaques and supports its advancement to a Phase I clinical trial.

DOI 10.1016/j.ymthe.2021.04.022

non-human primatemouse

𝕏 PostBluesky

BiochemistrybioRxivPreprintJun 5, 2020

Synthetic antibodies neutralize SARS-CoV-2 infection of mammalian cells

S. Miersch, M. Ustav, Z. Li…·S. S. Sidhu

The paper describes synthetic monoclonal antibodies that neutralize SARS-CoV-2 by binding to the spike protein and blocking ACE2 receptor interaction, showing potent antiviral activity.

DOI 10.1101/2020.06.05.137349

humanmouse

𝕏 PostBluesky